Neurocrine Biosciences Adds Dr. P. Brandon Davis to Board

TL;DR

NBIX adds pharma vet Dr. P. Brandon Davis to the board.

AI Summary

Neurocrine Biosciences, Inc. announced on May 22, 2024, the election of Dr. P. Brandon Davis to its Board of Directors, effective immediately. Dr. Davis, a seasoned executive with extensive experience in the pharmaceutical and biotechnology sectors, will serve as a Class II director. His appointment is part of the company's ongoing efforts to strengthen its leadership and strategic guidance.

Why It Matters

The addition of an experienced director like Dr. Davis can bring valuable strategic insights and industry connections, potentially influencing the company's future direction and growth.

Risk Assessment

Risk Level: low — The filing reports a routine board appointment, which typically carries low inherent risk.

Key Players & Entities

• Neurocrine Biosciences, Inc. (company) — Registrant
• Dr. P. Brandon Davis (person) — Newly elected Director
• May 22, 2024 (date) — Effective date of election

FAQ

Key Financial Figures

• $0.001 — nge on which registered Common Stock, $0.001 par value NBIX Nasdaq Global Select Mar

Filing Documents

• nbix-20240522.htm (8-K) — 42KB
• nbix-20240522_g1.jpg (GRAPHIC) — 18KB
• 0000914475-24-000140.txt ( ) — 212KB
• nbix-20240522.xsd (EX-101.SCH) — 2KB
• nbix-20240522_lab.xml (EX-101.LAB) — 21KB
• nbix-20240522_pre.xml (EX-101.PRE) — 12KB
• nbix-20240522_htm.xml (XML) — 3KB

07. Submission of Matters to a Vote of Security Holders

Item 5.07. Submission of Matters to a Vote of Security Holders. On May 22, 2024, the Company held its Annual Meeting. As of the close of business on March 25, 2024, the record date for the Annual Meeting, there were 100,580,497 shares of common stock entitled to vote, of which there were 90,166,107 shares present at the Annual Meeting in person or by proxy. At the Annual Meeting, stockholders voted on four matters: (i) the election of four Class I Directors for a term of three years expiring at the 2027 Annual Meeting of Stockholders, (ii) an advisory vote on the compensation paid to the Company's named executive officers, (iii) the approval of the Amended 2020 Plan, and (iv) the ratification of the appointment of Ernst & Young LLP as the Company's independent registered public accounting firm for the fiscal year ending December 31, 2024. The voting results were as follows: Election of four Class I Directors for a term of three years expiring at the 2027 Annual Meeting of Stockholders. Votes For Votes Withheld Broker Non-votes William H. Rastetter, Ph.D. 72,381,261 13,283,948 4,500,898 George J. Morrow 80,403,845 5,261,364 4,500,898 Leslie V. Norwalk 76,902,461 8,762,748 4,500,898 Christine A. Poon 80,898,676 4,766,533 4,500,898 The four nominees for Class I Director were elected. The Class II Directors, Richard F. Pops, Shalini Sharp, and Stephen A. Sherwin, M.D., will continue in office until the 2025 Annual Meeting of Stockholders or until their earlier death, resignation or removal. The Class III Directors, Kevin C. Gorman, Ph.D., Gary A. Lyons, and Johanna Mercier will continue in office until the 2026 Annual Meeting of Stockholders, or until their earlier death, resignation or removal. An advisory vote on the compensation paid to the Company's named executive officers. Votes For Votes Against Abstentions Broker Non-votes 80,281,842 4,276,395 1,106,972 4,500,898 The compensation of the Company's named executive officers, as disclosed in the P

SIGNATURES

SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. NEUROCRINE BIOSCIENCES, INC. Dated: May 23, 2024 /s/ Darin M. Lippoldt Darin M. Lippoldt Chief Legal Officer